ABVC BioPharma, Inc. (NASDAQ: ABVC) has filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, revealing a 179% year-over-year increase in total assets to $21,062,203, up from $7,539,907 in 2024. The growth is primarily attributed to strategic land acquisitions in Asia, with net property and equipment rising to $12,835,409 from $511,088. The company’s balance sheet now includes significant tangible assets, signaling a structural shift in its business model.
Management emphasized that the 2025 fiscal year represents a strengthening of the company’s asset foundation. As of December 31, 2025, ABVC reported $12.84 million in property and equipment (net), $1.91 million in operating lease right-of-use assets, and $1.88 million in long-term investments. The land acquisitions are in Taiwan, including 5,995.41 square meters in Longtan District, Taoyuan, valued at $4.6 million, and 69,230.90 square meters in Puli Township, Nantou, appraised at approximately $8.0 million as of January 30, 2026.
ABVC’s licensing structure remains central to its strategy. The company has licensed its core drug programs to subsidiaries and related parties: CNS pipeline to AiBtl BioPharma, oncology programs to OncoX BioPharma, and ophthalmology programs to ForSeeCon Eye Corporation. This model transfers clinical development risk while retaining licensing economics and equity participation. According to the filing, “this model has enabled ABVC to separate development risk from long-term value participation.”
The Puli property is planned as a staged, long-term initiative for a medicinal plant cultivation base, pharmaceutical supply chain localization, and an agricultural-biotech integration platform. Projected annual output value is estimated between $60,000 and $360,000, depending on processing depth. The Longtan property is held as a strategic reserve with potential for healthcare-related applications.
ABVC is evolving toward a hybrid asset model that combines intellectual property, licensing revenue, equity stakes in development subsidiaries, and tangible physical assets. The company’s pipeline includes six drugs and one medical device, Vitargus®, developed through partnerships with Stanford University, UCSF, and Cedars-Sinai Medical Center.
Forward-looking statements in the release highlight risks including manufacturing challenges, financing difficulties, competition, and regulatory approvals. More detailed risk factors are available in the company’s SEC filings at www.sec.gov.
